Hylenex (Wydase, Amphadase, Vitrase, Hydase, hyaluronidase)

Introduction

Tradenames: Wydase, Amphadase, Vitrase, Hydase, Hylenex (recominant)

Indications

• to increase the dispersion & absorption of other drugs
• increase the absorption of parenteral fluids given by hypodermoclysis
• enhance diffusion of locally irritating or toxic drugs in the management of IV extravasation

Contraindications

Caution:

• 0.02 mL intradermal test dose for sensitivity prior to administration

Dosage

• management of IV extravasation
  • reconstitute 150 unit vial of lyophylized powder with mL of normal saline
  • take 0.1 mL of this solution & dilute with 0.9 mL of normal saline to yield 15 units/mL
  • five 0.2 mL injections are made SC or intradermally into the extravasation site at the leading edge using a 25 or 26 gauge needle
  • change needle after each injection
• hypodermoclysis
  • add 15 units to each 200 mL of IV fluid to be administered by SC route
  • children: limit volume of single clysis to 200 mL
• absorption & dispertion of drugs
  • 150 units added to vehicle containing the drug

Injection: (lyophylized) 150 units

Injection: (solution) 150 units/mL (1 mL)

Amphadase, Hydase (bovine), Vitrase (ovine), Hylenex (human)

Adverse effects

• uncommon (< 1%)
  • tachycardia, hypotension, dizziness, urticaria, erythema, nausea/vomiting, chills

Mechanism of action

• hyaluronoglucosaminidase (hyaluronidase)

More general terms

• hyaluronoglucosaminidase; hyaluronidase (HYAL)
• metabolic agent (metabolic modifier)

Additional terms

• intravenous (IV) extravasation

Component of

• hylenex/trastuzumab
• hylenex/ocrelizumab
• hylenex/immune globulin
• efgartigimod/hylenex
• daratumumab/hylenex
• atezolizumab/hylenex